Peptide profile
IGF-1 LR3
Long-R3 insulin-like growth factor for muscle differentiation
Compare IGF-1 LR3 with other peptides →Summary
A long-lasting helper that helps your muscles grow and change.
- Typical dose
- 20-50mcg Daily post-workout
- Route
- Subcutaneous
- Cycle length
- 30-60 days
- Evidence
- Animal data
Mechanism
How it works
IGF-1 LR3 is like a key that stays in the lock longer — it keeps IGF receptors activated for extended anabolic signaling.
Long-R3 IGF-1 analog with reduced binding to IGF-binding proteins, leading to prolonged half-life and enhanced bioavailability.
Reported in research
Benefits
- Helps muscle strands grow and change
- Works great with PEG-MGF to make more muscle cells
- Helps your body hold on to nutrients for muscle
- Helps you heal faster after getting hurt
Context, not a prescription
Dosing
- Typical range
- 20-50mcg Daily post-workout (Subcutaneous)
- Cycle length
- 30-60 days
Safety
Side effects & contraindications
Possible side effects
- Hypoglycemia (mild)
- Joint pain
- Water retention
- Carpal tunnel syndrome
- Organomegaly (prolonged use)
- Acromegaly-like symptoms
Contraindications
- Active cancer (theoretical risk)
- Severe hypoglycemia
- Pregnancy or breastfeeding
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Muscle strands grow, your body uses food better, and you heal faster.
How it works
IGF-1 LR3 is like a key that stays in the lock longer. It keeps the muscle-building switch turned on for a longer time.
It grabs onto special spots on your cells very tightly. This turns on the body's signals to build muscle protein and grow.
What to expect
It starts working in a few hours. You can see muscle changes by 3-4 weeks.
- Days 1-7: Your body builds more muscle protein and heals better.
- Weeks 2-4: You slowly gain lean muscle.
- Weeks 6-8: Muscle growth reaches its peak.
Good to know
- Only use it after a workout
- Eat some carbs right away after
- Use it for short times (4-8 weeks)
Staying safe
- Blood sugar dropping a little
- Sore joints
- Holding extra water
Avoid if you have:
- People with cancer (it may not be safe)
- People whose blood sugar drops too low
- Women who are pregnant or breastfeeding
Mechanism of action
Long-R3 IGF-1 analog with reduced binding to IGF-binding proteins, leading to prolonged half-life and enhanced bioavailability.
Binds IGF-1 receptors with high affinity, activating PI3K/Akt and MAPK pathways for protein synthesis and differentiation.
Pharmacodynamics
Effects within hours; visible muscle changes by 3-4 weeks.
Muscle fiber growth (differentiation), improved nutrient partitioning, enhanced recovery.
Timeline
- Days 1-7: Enhanced protein synthesis and recovery.
- Weeks 2-4: Progressive lean mass gains.
- Weeks 6-8: Maximum anabolic effect.
Comparisons
- IGF-1 LR3 — effectiveness Moderate, safety Fair, cost $$, Medium to use
- PEG-MGF — effectiveness Emerging, safety Emerging, cost $$, Medium to use
Adverse effects
Common:
- Hypoglycemia (mild)
- Joint pain
- Water retention
Rare:
- Carpal tunnel syndrome
- Organomegaly (prolonged use)
- Acromegaly-like symptoms
Contraindications & risk mitigation
Contraindicated in:
- Active cancer (theoretical risk)
- Severe hypoglycemia
- Pregnancy or breastfeeding
- Use only post-workout
- Consume carbohydrates immediately after
- Short cycles (4-8 weeks)
Qué hace
Las fibras musculares crecen, tu cuerpo aprovecha mejor los alimentos y te recuperas más rápido.
Cómo funciona
IGF-1 LR3 es como una llave que se queda más tiempo en la cerradura. Mantiene el interruptor de construcción muscular encendido por más tiempo.
Se une con mucha fuerza a puntos especiales en tus células. Esto activa las señales del cuerpo para construir proteína muscular y crecer.
Qué esperar
Comienza a funcionar en unas horas. Puedes ver cambios musculares a las 3-4 semanas.
- Días 1-7: Tu cuerpo construye más proteína muscular y se recupera mejor.
- Semanas 2-4: Ganas músculo magro de forma gradual.
- Semanas 6-8: El crecimiento muscular alcanza su punto máximo.
Bueno saber
- Úsalo solo después de entrenar
- Come carbohidratos inmediatamente después
- Úsalo por períodos cortos (4-8 semanas)
Manteniéndose seguro
- Bajada leve del azúcar en sangre
- Dolor articular
- Retención de líquidos
Evitar si tienes:
- Personas con cáncer (podría no ser seguro)
- Personas con azúcar en sangre muy baja
- Mujeres embarazadas o en período de lactancia
Mecanismo de acción
Análogo de IGF-1 Long-R3 con menor unión a las proteínas fijadoras de IGF, lo que prolonga su vida media y mejora su biodisponibilidad.
Se une a los receptores de IGF-1 con alta afinidad, activando las vías PI3K/Akt y MAPK para la síntesis de proteínas y la diferenciación.
Farmacodinamia
Efectos en horas; cambios musculares visibles a las 3-4 semanas.
Crecimiento de las fibras musculares (diferenciación), mejor distribución de nutrientes y recuperación mejorada.
Cronología
- Días 1-7: Síntesis de proteínas y recuperación mejoradas.
- Semanas 2-4: Ganancias progresivas de masa magra.
- Semanas 6-8: Efecto anabólico máximo.
Comparaciones
- IGF-1 LR3 — efectividad Moderada, seguridad Aceptable, costo $$, Media de usar
- PEG-MGF — efectividad Emergente, seguridad Emergente, costo $$, Media de usar
Efectos adversos
Comunes:
- Hipoglucemia (leve)
- Dolor articular
- Retención de líquidos
Raros:
- Síndrome del túnel carpiano
- Organomegalia (uso prolongado)
- Síntomas similares a la acromegalia
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Cáncer activo (riesgo teórico)
- Hipoglucemia severa
- Embarazo o lactancia
- Usar solo después del entrenamiento
- Consumir carbohidratos inmediatamente después
- Ciclos cortos (4-8 semanas)
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 30-60 days
FAQ
Common questions
Does IGF-1 LR3 cause hypoglycemia?
Yes, mild hypoglycemia is common, especially if injected without food. Always consume carbohydrates post-injection.
Should I cycle IGF-1 LR3?
Yes, 4-8 weeks on followed by 4-8 weeks off to prevent receptor downregulation and side effects.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for IGF-1 LR3 is rated as Animal data. Research is based primarily on animal models.
- 1. IGF-1 LR3 pharmacology (2001) — DOI:10.1677/joe.0.1700473
- 2. IGF-1 and muscle growth (2011) — DOI:10.1152/japplphysiol.01119.2010
- 3. IGF-1 LR3 pharmacology (2001)
- 4. IGF-1 and muscle growth (2011)